Rossari Biotech Limited Approves Final Dividend, Notes Director Appointment, and Reschedules Capacity Expansion

Rossari Biotech Limited Approves Final Dividend, Notes Director Appointment, and Reschedules Capacity Expansion​

Rossari Biotech Limited announced several key approvals following its Board Meeting held on April 27, 2026. The company approved its audited financial results and statements for the quarter and the full financial year ended March 31, 2026. Additionally, the Board recommended a final dividend, approved the allotment of equity shares under the ESOP 2019, and updated its strategic plans for facility expansion.

Financial Results and Dividend Recommendation​

The Board of Directors reviewed and approved the audited financial results and statements for the quarter and the financial year ended March 31, 2026, along with the Statutory Auditor's Report.

The company recommended a final dividend of 25% (Re. 0.50 per share) on Equity Shares of the Face Value of Rs. 2 each for the Financial Year ended March 31, 2026. The dividend payment will be disbursed within 10 working days from the conclusion of the ensuing Annual General Meeting, subject to the Members' approval.

The company's financial performance data, including consolidated results, is detailed in the following summary statements:

Consolidated Statement of Financial Results


Standalone Statement of Financial Results

Key Corporate and Operational Updates​

Director Appointment
The Board appointed Mr. Udeypaul Singh Gill (DIN: 00004340) as an Additional Director designated as Non-Executive, Independent Director of the Company. His term of appointment will be for three consecutive years, commencing from April 28, 2026, up to April 27, 2029.

ESOP Allotment and Capital Structure
The Board also approved the allotment of 8,250 Equity Shares of Rs. 2 each, fully paid to the grantees under the Rossari Employee Stock Option Plan - 2019. With this allotment, the issued and paid-up equity share capital of the Company increased to Rs. 11,07,83,232, consisting of 55,391,616 Equity Shares of Rs. 2 each.

Strategic Facility Updates
Regarding infrastructure and development, the company made two key announcements:

1. New R&D Facility: Rossari Biotech Limited established a new Research and Development Facility at Navi Mumbai, located at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai - 400 710.
2. R&D Relocation: The Board approved the relocation and shifting of the Company's existing Research and Development Facility from IIT Bombay to the new facility in Navi Mumbai.

Capacity Expansion Project Update
The company informed stakeholders that it is re-evaluating the proposed capacity addition investment plan. Consequently, the implementation of the capacity expansion project is being rescheduled and is now expected to be undertaken in a phased manner over the next two years, maintaining the overall strategic intent.

***

Consolidated Financial Highlights (Year Ended March 31, 2026)​

The consolidated financials show the following annual performance data:


The cash flow statement for the year ended March 31, 2026, indicates a Net cash generated from operating activities of 650.68 million, compared to 1,374.43 million for the same period last year.

ROSSARI Stock Price Movement​

Rossari Biotech Limited shares today slipped by 2.17% to close at ₹504.2, shedding ₹11.20 from its previous close. Trading volume for the name recorded 279,177 shares during the session.